A method of treating a cholestasis liver condition in a subject in need of such therapy, comprising: coadministering to the subject a first compound and a second compound, wherein the first compound is selected from the group consisting of (1) a muricholic acid (MCA) or a pharmaceutically acceptable salt thereof, and (2) an apical sodium-dependent bile acid transporter (ASBT) inhibitor, and the second compound is selected from the group consisting of (1) a CYP7A1 inhibitor and (2) a bile acid-activated farnesoid x receptor (FXR) agonist. Examples of MCAs include α-MCA, β-MCA, ω-MCA, glycine-conjugated α-MCA (G-α-MCA), glycine-conjugated β-MCA (G-β-MCA), glycine-conjugated ω-MCA (G-ω-MCA), taurine-conjugated α-MCA (T-α-MCA), taurine-conjugated β-MCA (T-β-MCA), and taurine-conjugated ω-MCA (T-ω-MCA) and a pharmaceutically-acceptable salts of any of the above. The CYP7A1 inhibitor may be a fibroblast growth factor 15 (FGF15) or FGF15 analogue, a fibroblast growth factor 19 (FGF19) or FGF19 analogue, or an anti-CYP7A1 siRNA.